Neurobiology of Aging
Volume 29, Issue 3 , Pages 408-417 , March 2008

Early α-synuclein lipoxidation in neocortex in Lewy body diseases

Received 22 August 2006 ,Revised 30 September 2006 ,Accepted 18 October 2006.

References 

  1. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. A generalized increase in protein carbonyls in the brain in Parkinson's disease but not in incidental Lewy Body disease. J. Neurochem. 1997;69:1326–1329
  2. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 1997;69:1196–1203
  3. Baba M, Nakajo S, Tu PH, Tomita T, Lee VM, Trojanowski JQ, et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998;152:879–884
  4. Braak H, Braak E. Temporal sequence of Alzheimer's disease-related pathology. In:  Peters A,  Morrison JH editor. Cerebral Cortex. Neurodegenerative and Related Changes in Structure and Function of Cerebral Cortex. vol. 14:New York/Boston/Dordrecht/London/Moscow: Kluwer Academic/Plenum Publishers; 1999;p. 475–512
  5. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 2003;24:197–211
  6. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson's disease and Diffuse Lewy Body disease. Brain Res. 1996;737:195–200
  7. Ceballos I, Lafon M, Javoy-Agid F, Hirsch E, Nicole A, Sinet PM, et al. Superoxide dismutase and Parkinson's disease. Lancet. 1990;335:1035–1036
  8. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364:1105–1169
  9. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I, et al. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuropathol. Exp. Neurol. 2005;64:1–13
  10. Dexter D, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, et al. Lipid peroxidation as a cause of nigral death in Parkinson's disease. Lancet. 1986;2:639–640
  11. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 1989;52:381–389
  12. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 1994;35:38–44
  13. Dickson D. Tau and synuclein and their role in neuropathology. Brain Pathol. 1999;9:657–661
  14. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991;11:81–128
  15. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 1998;70:268–275
  16. Forno LS. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1996;55:259–272
  17. Giasson BI, Uryu K, Trojanowski JQ, Lee VM. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 1999;274:7619–7622
  18. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, et al. Oxidative stress induces amyloid-like aggregates formation of NACP/α-synuclein in vitro. NeuroReport. 1999;10:717–721
  19. Hashimoto M, Masliah E. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol. 1999;9:707–720
  20. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet. 2004;364:1169–1171
  21. Ince PG, McKeith I. Dementia with Lewy bodies. In:  Dickson D editors. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press; 2003;p. 188–199
  22. Ince PG, Perry EK, Morris CM. Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome?. Brain Pathol. 1998;8:299–324
  23. Iwatsubo T. Aggregation of α-synuclein in the pathogenesis of Parkinson's disease. J. Neurol. 2003;250(3):11–14
  24. Jellinger K, Mizuno Y. Parkinson's disease. In:  Dickson D editors. Neurodegeneration: The molecular pathology of dementia and movement disorders. Basel: ISN Neuropath Press; 2003;p. 159–187
  25. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 1998;13:24–34
  26. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003;53(3):S26–S38
  27. Kosaka K. Diffuse Lewy body disease in Japan. J. Neurol. 1990;237:197–204
  28. Kosaka K. Dementia and neuropathology in Lewy body disease. Adv. Neurol. 1993;60:456–463
  29. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 1998;18:106–108
  30. Markesberry WR, Montine TJ, Lovell MA. Oxidative alterations in neurodegenerative diseases. In:  Mattson MP editors. Pathogenesis of Neurodegenerative Diseases. Totowa, New Jersey: Humana Press; 2001;p. 21–51
  31. Marttila RJ, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J. Neurol. Sci. 1988;86:321–331
  32. McKeith IG, Ballard CG, Perry RH, Ince PG, O’Brien JT, Neill D, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54:1050–1058
  33. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology. 1996;47:1113–1124
  34. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, et al. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 1999;274:9843–9846
  35. Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 2006;59:298–309
  36. Norris EH, Giasson BI. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders. Antioxid. Redox Signal. 2005;7:672–684
  37. Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J. Neurochem. 2006;97:105–115
  38. Paik SR, Shin HJ, Lee JM. Metal-catalyzed oxidation of α-synuclein in the presence of Copper(II) and hydrogen peroxide. Arch. Biochem. Biophys. 2000;378:269–277
  39. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency. Neurosci. Lett. 1982;33:305–310
  40. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045–2047
  41. Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, et al. A selective increase in particulate superoxide dismutase activity in Parkinson's substantia nigra. J. Neurochem. 1989;53:692–697
  42. Sanchez-Ramos JR, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigrostriatum of Parkinson's disease brain. Neurodegeneration. 1994;3:197–204
  43. Shelley ML. 4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic. Biol. Med. 1998;25:169–174
  44. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, et al. Alterations in glutathione levels in Parkinson's disease patients. Ann. Neurol. 1994;36:348–355
  45. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841
  46. Slatter DA, Avery NC, Bailey AJ. Identification of a new cross-link and unique histidine adduct from bovine serum albumin incubated with malondialdehyde. J. Biol. Chem. 2004;279:61–69
  47. Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia. 2000;43:550–557
  48. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 2000;275:18344–18349
  49. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 1998;95:369–473
  50. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic. Biol. Med. 2000;28:1685–1696
  51. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 1996;93:696–701
  52. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004;55:164–173
  53. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, et al. Parkinson's disease is associated with oxidative damage to cytoplasmc DNA and RNA in substantia nigra neurons. Am. J. Pathol. 1999;154:1423–1429

PII: S0197-4580(06)00397-6

doi: 10.1016/j.neurobiolaging.2006.10.022

Neurobiology of Aging
Volume 29, Issue 3 , Pages 408-417 , March 2008

Article Tools

* Image Usage & Resolution